Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Invion ( (AU:IVX) ) is now available.
Invion Limited has made significant progress in its cancer treatment programs, highlighted by a $20,000 grant from the Colorectal Surgical Society of Australia and New Zealand Foundation to support an upcoming anogenital cancer clinical trial in collaboration with the Peter MacCallum Cancer Centre. The company has also advanced to Part 2 of its Phase I/II non-melanoma skin cancer trial, which showed promising early efficacy and potential diagnostic benefits. Additionally, Invion launched a Loyalty Option Entitlement Offer, raising approximately $1 million, with potential further funding if all options are exercised. These developments underscore Invion’s commitment to advancing its clinical programs and strengthening its financial position.
More about Invion
Invion Limited is a company operating in the biotechnology industry, focusing on developing treatments for cancer. The company is engaged in clinical trials and research, particularly in the areas of skin and anogenital cancers, leveraging innovative diagnostic and therapeutic techniques.
Average Trading Volume: 114,306
Technical Sentiment Signal: Sell
Current Market Cap: A$8.2M
See more data about IVX stock on TipRanks’ Stock Analysis page.